COGNITION THERAPEUTICS INC (CGTX)

Company Profile

Cognition Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for central nervous system disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 22 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases, such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy, and other conditions. The Company’s lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barriers to the S2R complex, and through its modulation, S2R restores the normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling lipid membrane-bound protein trafficking, and others.

Company Info

COGNITION THERAPEUTICS INC

Suite 261, 2403 Sidney Street

Pittsburgh PENNSYLVANIA

P: 14127701621

Employees: 22

Website: https://cogrx.com/